McKesson Corporation stock (US58155Q1031): dividend date and recent earnings in focus

McKesson Corporation shares continue to trade near record levels on the New York Stock Exchange as investors digest the latest quarterly results and look ahead to the June dividend payment date in the United States healthcare distribution group.

McKesson Corporation shares were changing hands close to recent highs on the New York Stock Exchange on 06/02/2026 as investors weighed the company’s latest quarterly numbers and an upcoming dividend payment in the United States healthcare distribution group.

The stock most recently traded around the mid-USD 640s on NYSE under the ticker MCK, according to exchange data as of late May 2026, keeping the company among the higher-priced names in the S&P 500 healthcare segment. McKesson had previously announced a regular quarterly dividend of USD 0.62 per share, with a payment date in late June 2026 for shareholders of record earlier in the month, as stated in a company dividend declaration filed on 05/01/2026.

The stock traded at 651.20 EUR on 06/01/2026 on Tradegate in Germany, with an intraday change of 0.09%, illustrating sustained international investor interest in the healthcare distributor’s equity. In the home market United States, the pricing remains anchored in US dollars on the NYSE, and the shares are widely followed by institutional investors due to the company’s role in the domestic pharmaceutical supply chain.

On the fundamental side, the most recent quarterly results were presented on 05/08/2026 for the company’s fiscal fourth quarter and full fiscal year 2026, according to a press release on McKesson’s investor relations site. In that update the company reported fiscal Q4 2026 revenues of approximately USD 80.9 billion and adjusted earnings per diluted share of USD 7.80, while full-year fiscal 2026 revenues reached roughly USD 313.5 billion and adjusted EPS came in at USD 27.50, demonstrating the scale of its U.S.-centered distribution operations.

Management also provided guidance for the new fiscal year 2027 in the 05/08/2026 release, indicating an adjusted EPS range of USD 29.00 to USD 30.50, subject to typical assumptions on prescription volumes, branded and generic drug pricing, and ongoing share repurchases. The outlook places the company’s expected earnings trajectory firmly within the context of the U.S. healthcare reimbursement environment, which remains influenced by Medicare, Medicaid and private-payer dynamics.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: McKesson
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Irving, United States
• Core markets: United States, with selected activities in Canada and Europe
• Key revenue drivers: U.S. pharmaceutical distribution, specialty and oncology solutions, medical-surgical distribution, and technology-enabled healthcare services
• Home exchange/listing venue: New York Stock Exchange (MCK)
• Trading currency: USD

McKesson Corporation: core business model

McKesson primarily operates as a large-scale healthcare logistics and services provider, channeling prescription medicines, medical supplies and related solutions to pharmacies, hospitals and other care providers, with most of its revenue generated from U.S. pharmaceutical distribution and complementary service contracts.

Latest quarterly results for McKesson Corporation at a glance

In its fiscal Q4 2026 earnings release on 05/08/2026, McKesson reported revenues of approximately USD 80.9 billion, up from around USD 76.4 billion in the prior-year quarter, reflecting volume growth and mix effects in its U.S. pharmaceutical and specialty segments, according to the company’s investor presentation and press materials. Adjusted earnings per diluted share for the quarter were USD 7.80 versus USD 7.19 one year earlier, as the company benefited from operational efficiencies, margin contributions from specialty distribution and an ongoing share repurchase program that lowered the diluted share count.

For the full fiscal year 2026, McKesson disclosed total revenues of about USD 313.5 billion compared with approximately USD 301.5 billion in fiscal 2025, maintaining its position as one of the largest revenue generators in the U.S. healthcare sector, as shown in the same 05/08/2026 filing. Full-year adjusted EPS reached USD 27.50, up from USD 25.28 in the previous fiscal year, and management’s guidance for fiscal 2027 pointed to adjusted EPS in a range of USD 29.00 to USD 30.50, implying further modest earnings expansion assuming stable prescription utilization, continued generics penetration and disciplined capital allocation.

Conclusion

McKesson Corporation’s share price around the mid-USD 600s reflects investor attention on its large U.S. healthcare distribution franchise, supported by robust fiscal 2026 revenue and earnings figures disclosed on 05/08/2026 and a steady quarterly dividend profile. The latest quarterly release and guidance for fiscal 2027 provide updated reference points for how the company expects prescription volumes, generic trends and capital allocation to translate into earnings over the coming year, while the upcoming June dividend payment anchors a predictable cash-return element for shareholders without changing the fundamentally operational nature of the investment case.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.